Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
GlobeNewswire
· Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a..
